Database Query Results : Luteolin, ,

LT, Luteolin: Click to Expand ⟱
Features:
Luteolin a Flavonoid found in celery, parsley, broccoli, onion leaves, carrots, peppers, cabbages, apple skins, and chrysanthemum flowers.
-MDR1 expression, MMP-9, IGF-1 and Epithelial to mesenchymal transition.

*** ACTIVE WORK IN PROGRESS**

-Note half-life 2–3 hours
BioAv low, but could be improved with Res, or blend of castor oil, kolliphor and polyethylene glycol
Pathways:
- induce ROS production in cancer cell but a few reports of reduction. Always seems to reduce ROS in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓
- Lowers AntiOxidant defense in Cancer Cells: NRF2↓, SOD↓, GSH↓ Catalase↓ HO1↓ GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : IL-1β↓, TNF-α↓, IL-6↓,
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMP2↓, MMP9↓, TIMP2, IGF-1↓, VEGF↓, FAK↓, RhoA↓, NF-κB↓, CXCR4↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMT1↓, DNMT3A↓, EZH2↓, P53↑, HSP↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, FAK↓, ERK↓, EMT↓, TOP1↓, TET1↓,
- inhibits glycolysis and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, LDHA↓, HK2↓, GRP78↑,
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, PDGF↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, JNK, TrxR**, - Shown to modulate the nuclear translocation of SREBP-2 (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, Others(review target notes), Neuroprotective, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells


Scientific Papers found: Click to Expand⟱
1539- Api,  LT,    Dietary flavones counteract phorbol 12-myristate 13-acetate-induced SREBP-2 processing in hepatic cells
- in-vitro, Liver, HepG2
"highlight2" >SREBP2↓, "highlight2" >eff↑, "highlight2" >p‑MEK↓, "highlight2" >p‑ERK↓,
2596- Api,  LT,    Natural Nrf2 Inhibitors: A Review of Their Potential for Cancer Treatment
- Review, Var, NA
"highlight2" >NRF2↓, "highlight2" >chemoP↑,
2625- Ba,  LT,    Baicalein and luteolin inhibit ischemia/reperfusion-induced ferroptosis in rat cardiomyocyte
- in-vivo, Stroke, NA
"highlight2" >*lipid-P↓, "highlight2" >*ACSL4∅, "highlight2" >*NRF2∅, "highlight2" >*GPx4∅, "highlight2" >*Ferroptosis↓, "highlight2" >*ROS↓, "highlight2" >*MDA↓, "highlight2" >*eff↑, "highlight2" >*HO-1∅,
3633- BBR,  LT,  Croc,  QC,    Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy
- Review, AD, NA
"highlight2" >*AChE↓, "highlight2" >*AChE↓,
2917- LT,  Rad,    Luteolin acts as a radiosensitizer in non‑small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade
- in-vitro, Lung, NA
"highlight2" >Bcl-2↓, "highlight2" >Casp3↑, "highlight2" >Casp8↑, "highlight2" >Casp9↑, "highlight2" >p‑p38↑, "highlight2" >ROS↑, "highlight2" >RadioS↑,
2922- LT,    Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC
- in-vitro, Liver, HUH7
"highlight2" >Half-Life↝, "highlight2" >TumCCA↑, "highlight2" >AKT1↓, "highlight2" >ATF2↓, "highlight2" >NF-kB↓, "highlight2" >GSK‐3β↓, "highlight2" >cMyc↓, "highlight2" >GSTs↓, "highlight2" >TrxR1↓, "highlight2" >ROS↑,
2921- LT,    Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies
- Review, Nor, NA
"highlight2" >*hepatoP↑, "highlight2" >*AMPK↑, "highlight2" >*SIRT1↑, "highlight2" >*ROS↓, "highlight2" >STAT3↓, "highlight2" >TNF-α↓, "highlight2" >NF-kB↓, "highlight2" >*IL2↓, "highlight2" >*IFN-γ↓, "highlight2" >*GSH↑, "highlight2" >*SREBP1↓, "highlight2" >*ZO-1↑, "highlight2" >*TLR4↓, "highlight2" >BAX↑, "highlight2" >Bcl-2↓, "highlight2" >XIAP↓, "highlight2" >Fas↑, "highlight2" >Casp8↑, "highlight2" >Beclin-1↑, "highlight2" >*TXNIP↓, "highlight2" >*Casp1↓, "highlight2" >*IL1β↓, "highlight2" >*IL18↓, "highlight2" >*NLRP3↓, "highlight2" >*MDA↓, "highlight2" >*SOD↑, "highlight2" >*NRF2↑, "highlight2" >*ER Stress↓, "highlight2" >*ALAT↓, "highlight2" >*AST↓, "highlight2" >*iNOS↓, "highlight2" >*IL6↓, "highlight2" >*HO-1↑, "highlight2" >*NQO1↑, "highlight2" >*PPARα↑, "highlight2" >*ATF4↓, "highlight2" >*CHOP↓, "highlight2" >*Inflam↓, "highlight2" >*antiOx↑, "highlight2" >*GutMicro↑,
2920- LT,    Formulation, characterization, in vitro and in vivo evaluations of self-nanoemulsifying drug delivery system of luteolin
- in-vitro, Nor, NA - in-vivo, Nor, NA
"highlight2" >BioAv↑, "highlight2" >eff↑,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
"highlight2" >RadioS↑, "highlight2" >ChemoSen↑, "highlight2" >chemoP↑, "highlight2" >*lipid-P↓, "highlight2" >*Catalase↑, "highlight2" >*SOD↑, "highlight2" >*GPx↑, "highlight2" >*GSTs↑, "highlight2" >*GSH↑, "highlight2" >*TNF-α↓, "highlight2" >*IL1β↓, "highlight2" >*Casp3↓, "highlight2" >*IL10↑, "highlight2" >NRF2↓, "highlight2" >HO-1↓, "highlight2" >NQO1↓, "highlight2" >GSH↓, "highlight2" >MET↓, "highlight2" >p‑MET↓, "highlight2" >p‑Akt↓, "highlight2" >HGF/c-Met↓, "highlight2" >NF-kB↓, "highlight2" >Bcl-2↓, "highlight2" >SOD2↓, "highlight2" >Casp8↑, "highlight2" >Casp3↑, "highlight2" >PARP↑, "highlight2" >MAPK↓, "highlight2" >NLRP3↓, "highlight2" >ASC↓, "highlight2" >Casp1↓, "highlight2" >IL6↓, "highlight2" >IKKα↓, "highlight2" >p‑p65↓, "highlight2" >p‑p38↑, "highlight2" >MMP2↓, "highlight2" >ICAM-1↓, "highlight2" >EGFR↑, "highlight2" >p‑PI3K↓, "highlight2" >E-cadherin↓, "highlight2" >ZO-1↑, "highlight2" >N-cadherin↓, "highlight2" >CLDN1↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >Snail↓, "highlight2" >Vim↑, "highlight2" >ITGB1↓, "highlight2" >FAK↓, "highlight2" >p‑Src↓, "highlight2" >Rac1↓, "highlight2" >Cdc42↓, "highlight2" >Rho↓, "highlight2" >PCNA↓, "highlight2" >Tyro3↓, "highlight2" >AXL↓, "highlight2" >CEA↓, "highlight2" >NSE↓, "highlight2" >SOD↓, "highlight2" >Catalase↓, "highlight2" >GPx↓, "highlight2" >GSR↓, "highlight2" >GSTs↓, "highlight2" >GSH↓, "highlight2" >VitE↓, "highlight2" >VitC↓, "highlight2" >CYP1A1↓, "highlight2" >cFos↑, "highlight2" >AR↓, "highlight2" >AIF↑, "highlight2" >p‑STAT6↓, "highlight2" >p‑MDM2↓, "highlight2" >NOTCH1↓, "highlight2" >VEGF↓, "highlight2" >H3↓, "highlight2" >H4↓, "highlight2" >HDAC↓, "highlight2" >SIRT1↓, "highlight2" >ROS↑, "highlight2" >DR5↑, "highlight2" >Cyt‑c↑, "highlight2" >p‑JNK↑, "highlight2" >PTEN↓, "highlight2" >mTOR↓, "highlight2" >CD34↓, "highlight2" >FasL↑, "highlight2" >Fas↑, "highlight2" >XIAP↓, "highlight2" >p‑eIF2α↑, "highlight2" >CHOP↑, "highlight2" >LC3II↑, "highlight2" >PD-1↓, "highlight2" >STAT3↓, "highlight2" >IL2↑, "highlight2" >EMT↓, "highlight2" >cachexia↓, "highlight2" >BioAv↑, "highlight2" >*Half-Life↝, "highlight2" >*eff↑,
2918- LT,    Luteolin inhibits melanoma growth in vitro and in vivo via regulating ECM and oncogenic pathways but not ROS
- in-vitro, Melanoma, A375 - in-vivo, Melanoma, NA - in-vitro, Melanoma, SK-MEL-28
"highlight2" >TumCG↓, "highlight2" >ROS↑, "highlight2" >ECM/TCF↓,
2911- LT,    Luteolin targets MKK4 to attenuate particulate matter-induced MMP-1 and inflammation in human keratinocytes
- in-vitro, Nor, HaCaT
"highlight2" >*MMP1↓, "highlight2" >*COX2↓, "highlight2" >*IL6↓, "highlight2" >*AP-1↓, "highlight2" >*NF-kB↓, "highlight2" >*ROS↓, "highlight2" >*p‑MKK4↑, "highlight2" >*p‑JNK↓, "highlight2" >*p‑p38↓,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
"highlight2" >proCasp9↓, "highlight2" >CDC2↓, "highlight2" >CycB↓, "highlight2" >Casp9↑, "highlight2" >Casp3↑, "highlight2" >Cyt‑c↑, "highlight2" >cycA1↑, "highlight2" >CDK2↓, "highlight2" >APAF1↑, "highlight2" >TumCCA↑, "highlight2" >P53↑, "highlight2" >BAX↑, "highlight2" >VEGF↓, "highlight2" >Bcl-2↓, "highlight2" >Apoptosis↑, "highlight2" >p‑Akt↓, "highlight2" >p‑EGFR↓, "highlight2" >p‑ERK↓, "highlight2" >p‑STAT3↓, "highlight2" >cardioP↑, "highlight2" >Catalase↓, "highlight2" >SOD↓, "highlight2" >*BioAv↓, "highlight2" >*antiOx↑, "highlight2" >*ROS↓, "highlight2" >*NO↓, "highlight2" >*GSTs↑, "highlight2" >*GSR↑, "highlight2" >*SOD↑, "highlight2" >*Catalase↑, "highlight2" >*lipid-P↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >CDK2↓, "highlight2" >BNIP3↑, "highlight2" >hTERT↓, "highlight2" >DR5↑, "highlight2" >Beclin-1↑, "highlight2" >TNF-α↓, "highlight2" >NF-kB↓, "highlight2" >IL1↓, "highlight2" >IL6↓, "highlight2" >EMT↓, "highlight2" >FAK↓, "highlight2" >E-cadherin↑, "highlight2" >MDM2↓, "highlight2" >NOTCH↓, "highlight2" >MAPK↑, "highlight2" >Vim↓, "highlight2" >N-cadherin↓, "highlight2" >Snail↓, "highlight2" >MMP2↓, "highlight2" >Twist↓, "highlight2" >MMP9↓, "highlight2" >ROS↑, "highlight2" >MMP↓, "highlight2" >*AChE↓, "highlight2" >*MMP↑, "highlight2" >*Aβ↓, "highlight2" >*neuroP↑, "highlight2" >Trx1↑, "highlight2" >ROS↓, "highlight2" >*NRF2↑, "highlight2" >NRF2↓, "highlight2" >*BBB↑, "highlight2" >ChemoSen↑, "highlight2" >GutMicro↑,
2915- LT,    Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells
- in-vitro, Colon, HT29 - in-vitro, CRC, SNU-407 - in-vitro, Nor, FHC
"highlight2" >DNMTs↓, "highlight2" >TET1↑, "highlight2" >NRF2↑, "highlight2" >HDAC↓, "highlight2" >tumCV↓, "highlight2" >BAX↑, "highlight2" >Casp9↑, "highlight2" >Casp3↑, "highlight2" >Bcl-2↓, "highlight2" >ROS↓, "highlight2" >GSS↑, "highlight2" >Catalase↑, "highlight2" >HO-1↑, "highlight2" >DNMT1↓, "highlight2" >DNMT3A↓, "highlight2" >TET1↑, "highlight2" >TET3↑, "highlight2" >TET2↓, "highlight2" >P53↑, "highlight2" >P21↑,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
"highlight2" >*antiOx↑, "highlight2" >*IronCh↑, "highlight2" >*toxicity↓, "highlight2" >*BioAv↓, "highlight2" >*BioAv↑, "highlight2" >DNAdam↑, "highlight2" >TumCP↓, "highlight2" >DR5↑, "highlight2" >P53↑, "highlight2" >JNK↑, "highlight2" >BAX↑, "highlight2" >cl‑Casp3↑, "highlight2" >cl‑Casp8↑, "highlight2" >cl‑Casp9↑, "highlight2" >cl‑PARP↑, "highlight2" >survivin↓, "highlight2" >cycD1↓, "highlight2" >CycB↓, "highlight2" >CDC2↓, "highlight2" >P21↑, "highlight2" >angioG↓, "highlight2" >MMP2↓, "highlight2" >AEG1↓, "highlight2" >VEGF↓, "highlight2" >VEGFR2↓, "highlight2" >MMP9↓, "highlight2" >CXCR4↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >ERK↓, "highlight2" >TumAuto↑, "highlight2" >LC3B-II↑, "highlight2" >EMT↓, "highlight2" >E-cadherin↑, "highlight2" >N-cadherin↓, "highlight2" >Wnt↓, "highlight2" >ROS↑, "highlight2" >NICD↓, "highlight2" >p‑GSK‐3β↓, "highlight2" >iNOS↓, "highlight2" >COX2↓, "highlight2" >NRF2↑, "highlight2" >Ca+2↑, "highlight2" >ChemoSen↑, "highlight2" >ChemoSen↓, "highlight2" >IFN-γ↓, "highlight2" >RadioS↑, "highlight2" >MDM2↓, "highlight2" >NOTCH1↓, "highlight2" >AR↓, "highlight2" >TIMP1↑, "highlight2" >TIMP2↑, "highlight2" >ER Stress↑, "highlight2" >CDK2↓, "highlight2" >Telomerase↓, "highlight2" >p‑NF-kB↑, "highlight2" >p‑cMyc↑, "highlight2" >hTERT↓, "highlight2" >RAS↓, "highlight2" >YAP/TEAD↓, "highlight2" >TAZ↓, "highlight2" >NF-kB↓, "highlight2" >NRF2↓, "highlight2" >HO-1↓, "highlight2" >MDR1↓,
2913- LT,    Luteolin induces apoptosis by impairing mitochondrial function and targeting the intrinsic apoptosis pathway in gastric cancer cells
- in-vitro, GC, HGC27 - in-vitro, BC, MCF-7 - in-vitro, GC, MKN45
"highlight2" >TumCP↓, "highlight2" >MMP↓, "highlight2" >Apoptosis↑, "highlight2" >ROS↑, "highlight2" >SOD↓, "highlight2" >ATP↓, "highlight2" >Bax:Bcl2↑, "highlight2" >TumCCA↑,
2912- LT,    Luteolin: a flavonoid with a multifaceted anticancer potential
- Review, Var, NA
"highlight2" >ROS↑, "highlight2" >TumCCA↑, "highlight2" >TumCP↓, "highlight2" >angioG↓, "highlight2" >ER Stress↑, "highlight2" >mtDam↑, "highlight2" >PERK↑, "highlight2" >ATF4↑, "highlight2" >eIF2α↑, "highlight2" >cl‑Casp12↑, "highlight2" >EMT↓, "highlight2" >E-cadherin↑, "highlight2" >N-cadherin↓, "highlight2" >Vim↓, "highlight2" >*neuroP↑, "highlight2" >NF-kB↓, "highlight2" >PI3K↓, "highlight2" >Akt↑, "highlight2" >XIAP↓, "highlight2" >MMP↓, "highlight2" >Ca+2↑, "highlight2" >BAX↑, "highlight2" >Casp3↑, "highlight2" >Casp9↑, "highlight2" >Bcl-2↓, "highlight2" >Cyt‑c↑, "highlight2" >IronCh↑, "highlight2" >SOD↓, "highlight2" >*ROS↓, "highlight2" >*LDHA↑, "highlight2" >*SOD↑, "highlight2" >*GSH↑, "highlight2" >*BioAv↓, "highlight2" >Telomerase↓, "highlight2" >cMyc↓, "highlight2" >hTERT↓, "highlight2" >DR5↑, "highlight2" >Fas↑, "highlight2" >FADD↑, "highlight2" >BAD↑, "highlight2" >BOK↑, "highlight2" >BID↑, "highlight2" >NAIP↓, "highlight2" >Mcl-1↓, "highlight2" >CDK2↓, "highlight2" >CDK4↓, "highlight2" >MAPK↓, "highlight2" >AKT1↓, "highlight2" >Akt2↓, "highlight2" >*Beclin-1↓, "highlight2" >Hif1a↓, "highlight2" >LC3II↑, "highlight2" >Beclin-1↑,
2909- LT,    Revisiting luteolin: An updated review on its anticancer potential
- Review, Var, NA
"highlight2" >Apoptosis↑, "highlight2" >TumCCA↑, "highlight2" >angioG↓, "highlight2" >TumMeta↓, "highlight2" >TumCP↓, "highlight2" >chemoP↑, "highlight2" >MDR1↓,
2923- LT,    Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells
- in-vitro, NA, NA
"highlight2" >Apoptosis↑, "highlight2" >TumCD↑, "highlight2" >Casp12↑, "highlight2" >Casp9↑, "highlight2" >Casp3↑, "highlight2" >ER Stress↑, "highlight2" >CHOP↑, "highlight2" >GRP78/BiP↑, "highlight2" >GRP94↑, "highlight2" >cl‑ATF6↑, "highlight2" >p‑eIF2α↑, "highlight2" >MMP↓, "highlight2" >JNK↓, "highlight2" >p38↑, "highlight2" >ERK↑, "highlight2" >Cyt‑c↑,
2924- LT,    Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1
- in-vitro, GC, NA - in-vivo, NA, NA
"highlight2" >p‑STAT3↓, "highlight2" >STAT3↓, "highlight2" >Mcl-1↓, "highlight2" >survivin↓, "highlight2" >Bcl-xL↓, "highlight2" >HSP90↓,
2925- LT,    Luteolin Induces Carcinoma Cell Apoptosis through Binding Hsp90 to Suppress Constitutive Activation of STAT3
- in-vitro, Cerv, HeLa - in-vitro, Nor, HEK293 - in-vitro, BC, MCF-7
"highlight2" >HSP90↓, "highlight2" >p‑STAT3↓, "highlight2" >Apoptosis↑, "highlight2" >selectivity↑,
2926- LT,    Luteolin ameliorates rat myocardial ischemia-reperfusion injury through peroxiredoxin II activation: LUT's cardioprotection through PRX II
- in-vitro, Nor, H9c2
"highlight2" >*cardioP↑, "highlight2" >*PrxII↑,
2927- LT,    Luteolin Causes 5′CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells
- in-vitro, Cerv, HeLa
"highlight2" >TumCMig↓, "highlight2" >DNMTs↓, "highlight2" >HDAC↓, "highlight2" >HATs↓, "highlight2" >ac‑H3↓, "highlight2" >ac‑H4↓, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >HO-1↓, "highlight2" >E-cadherin↑, "highlight2" >EZH2↓, "highlight2" >HER2/EBBR2↓, "highlight2" >IL18↓, "highlight2" >IL8↓, "highlight2" >IL2↓,
2928- LT,    Luteolin-mediated increase in miR-26a inhibits prostate cancer cell growth and induces cell cycle arrest targeting EZH2
"highlight2" >EZH2↓, "highlight2" >cycD1↓, "highlight2" >cycE↓, "highlight2" >CDK4↓, "highlight2" >CDK6↓,
2929- LT,    Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention
- in-vitro, Ovarian, NA
"highlight2" >HK2↓, "highlight2" >Myc↓, "highlight2" >Glycolysis↓,
2930- LT,    Luteolin confers renoprotection against ischemia–reperfusion injury via involving Nrf2 pathway and regulating miR320
- in-vitro, Nor, NA
"highlight2" >*RenoP↑, "highlight2" >*ROS↓, "highlight2" >*antiOx↑, "highlight2" >*NRF2↓,
4292- LT,    Luteolin for neurodegenerative diseases: a review
- Review, AD, NA - Review, Park, NA - Review, MS, NA - Review, Stroke, NA
"highlight2" >*Inflam↓, "highlight2" >*antiOx↑, "highlight2" >*neuroP↑, "highlight2" >*BioAv↝, "highlight2" >*BBB↑, "highlight2" >*TNF-α↓, "highlight2" >*IL1β↓, "highlight2" >*IL6↓, "highlight2" >*IL8↓, "highlight2" >*IL33↓, "highlight2" >*NF-kB↓, "highlight2" >*BACE↓, "highlight2" >*ROS↓, "highlight2" >*SOD↑, "highlight2" >*HO-1↑, "highlight2" >*NRF2↑, "highlight2" >*Casp3↓, "highlight2" >*Casp9↑, "highlight2" >*Bax:Bcl2↓, "highlight2" >*UPR↑, "highlight2" >*GRP78/BiP↑, "highlight2" >*Aβ↓, "highlight2" >*GSK‐3β↓, "highlight2" >*tau↓, "highlight2" >*CREB↑, "highlight2" >*ATP↑, "highlight2" >*cognitive↑, "highlight2" >*BloodF↑, "highlight2" >*BDNF↑, "highlight2" >*TrkB↑, "highlight2" >*memory↑, "highlight2" >*PPARγ↑, "highlight2" >*eff↑,
4293- LT,    Regulatory Role of NF-κB on HDAC2 and Tau Hyperphosphorylation in Diabetic Encephalopathy and the Therapeutic Potential of Luteolin
- in-vivo, Diabetic, NA
"highlight2" >*Inflam↓, "highlight2" >*antiOx↑, "highlight2" >*neuroP↑, "highlight2" >*cognitive↑, "highlight2" >*p‑mTOR↓, "highlight2" >*p‑NF-kB↓, "highlight2" >*HDAC2↓, "highlight2" >*BDNF↑, "highlight2" >*other↓, "highlight2" >*p‑tau↓,
4294- LT,    Luteolin reduces zinc-induced tau phosphorylation at Ser262/356 in an ROS-dependent manner in SH-SY5Y cells
- in-vitro, NA, SH-SY5Y
"highlight2" >*tau↓, "highlight2" >*antiOx↑,
4295- LT,    Luteolin Reduces Alzheimer’s Disease Pathologies Induced by Traumatic Brain Injury
- in-vivo, AD, NA
"highlight2" >*Aβ↓, "highlight2" >*GSK‐3β↓, "highlight2" >*p‑tau↓, "highlight2" >*BBB↑,
4338- LT,    Luteolin: a natural product with multiple mechanisms for atherosclerosis
- Review, NA, NA
"highlight2" >*Inflam↓, "highlight2" >*ROS↓, "highlight2" >*PDGF↓, "highlight2" >*lipid-P↓, "highlight2" >*AMPK↑, "highlight2" >*SIRT1↑, "highlight2" >*AntiAg↑,
4339- LT,    Luteolin inhibits GPVI-mediated platelet activation, oxidative stress, and thrombosis
- in-vivo, NA, NA
"highlight2" >*AntiAg↑, "highlight2" >*ROS↓,
1534- LT,  Api,  EGCG,  RES,    Plant polyphenol induced cell death in human cancer cells involves mobilization of intracellular copper ions and reactive oxygen species generation: a mechanism for cancer chemopreventive action
- in-vitro, Nor, MCF10 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468 - in-vitro, PC, Bxpc-3
"highlight2" >TumCP↓, "highlight2" >Apoptosis↑, "highlight2" >eff↓, "highlight2" >*toxicity↑, "highlight2" >Dose?, "highlight2" >eff↓, "highlight2" >eff↓,
979- LT,    Luteolin Regulation of Estrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast Cancer Cells
- in-vitro, BC, MCF-7
"highlight2" >TumCP↓,
982- LT,    Inhibitory effect of luteolin on estrogen biosynthesis in human ovarian granulosa cells by suppression of aromatase (CYP19)
- in-vitro, Ovarian, KGN
"highlight2" >CYP19↓,
986- LT,  doxoR,    Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells
- in-vitro, BC, 4T1 - in-vitro, BC, MCF-7
"highlight2" >SOD↓, "highlight2" >Catalase↓, "highlight2" >Glycolysis↓,
1025- LT,  Api,    Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer
- in-vivo, Lung, NA
"highlight2" >TumCG↓, "highlight2" >Apoptosis↑, "highlight2" >PD-L1↓, "highlight2" >p‑STAT3↓,
1060- LT,  BTZ,    Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma
- vitro+vivo, Melanoma, NA
"highlight2" >ALDH1A1↓, "highlight2" >TGF-β↓, "highlight2" >ChemoSen↑,
1064- LT,  Cisplatin,    Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells
- vitro+vivo, Lung, LNM35 - in-vitro, CRC, HT-29 - in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
"highlight2" >Casp3↑, "highlight2" >Casp7↑, "highlight2" >HDAC↓,
1084- LT,  CHr,    Luteolin and chrysin differentially inhibit cyclooxygenase-2 expression and scavenge reactive oxygen species but similarly inhibit prostaglandin-E2 formation in RAW 264.7 cells
- in-vitro, Nor, RAW264.7
"highlight2" >*COX2↓, "highlight2" >*COX2∅, "highlight2" >*PGE2↓, "highlight2" >*ROS↓,
1100- LT,    Luteolin, a flavonoid, as an anticancer agent: A review
- Review, NA, NA
"highlight2" >TumCP↓, "highlight2" >TumCCA↑, "highlight2" >Apoptosis↑, "highlight2" >EMT↓, "highlight2" >E-cadherin↑, "highlight2" >N-cadherin↓, "highlight2" >Snail↓, "highlight2" >Vim↓, "highlight2" >ROS↑, "highlight2" >ER Stress↑, "highlight2" >mtDam↑, "highlight2" >p‑eIF2α↝, "highlight2" >p‑PERK↝, "highlight2" >p‑CHOP↝, "highlight2" >p‑ATF4↝, "highlight2" >cl‑Casp12↝,
1125- LT,    Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity
- in-vitro, BC, NA
"highlight2" >YAP/TEAD↓, "highlight2" >TAZ↓, "highlight2" >MSCmark↓, "highlight2" >EM↑, "highlight2" >TumCMig↓,
1171- LT,    The inhibition of β-catenin activity by luteolin isolated from Paulownia flowers leads to growth arrest and apoptosis in cholangiocarcinoma
- in-vitro, CCA, NA
"highlight2" >Wnt↓, "highlight2" >TumCCA↑, "highlight2" >Apoptosis↑, "highlight2" >TumCMig↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >cMyc↓, "highlight2" >cycD1↓,
1200- LT,    Inhibition of Fatty Acid Synthase by Luteolin Post-Transcriptionally Downregulates c-Met Expression Independent of Proteosomal/Lysosomal Degradation
- in-vitro, Pca, DU145
"highlight2" >FASN↓, "highlight2" >cMET↓, "highlight2" >HGF/c-Met↓,
1275- LT,    Mechanism of luteolin induces ferroptosis in nasopharyngeal carcinoma cells
- in-vitro, Laryn, NA
"highlight2" >Ferroptosis↑, "highlight2" >MDA↑, "highlight2" >Iron↑, "highlight2" >SOD↓, "highlight2" >GSH↓, "highlight2" >GPx4↓, "highlight2" >SOX4↓, "highlight2" >GDF15↓,
1317- LT,    Luteolin Suppresses Teratoma Cell Growth and Induces Cell Apoptosis via Inhibiting Bcl-2
- vitro+vivo, Ovarian, PA1
"highlight2" >Bcl-2↓, "highlight2" >BAX↑, "highlight2" >Apoptosis↑, "highlight2" >TumCG↓,
2910- LT,  FA,    Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment
- in-vitro, BC, 4T1 - in-vivo, NA, NA
"highlight2" >BioAv↓, "highlight2" >BioAv↑, "highlight2" >eff↑, "highlight2" >tumCV↓, "highlight2" >e-H2O2↓, "highlight2" >i-H2O2∅,
2346- LT,    Luteolin suppressed PKM2 and promoted autophagy for inducing the apoptosis of hepatocellular carcinoma cells
- in-vitro, HCC, HepG2
"highlight2" >TumCP↓, "highlight2" >Apoptosis↓, "highlight2" >PKM2↓, "highlight2" >TumAuto↑,
2587- LT,    Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs
- in-vitro, Lung, A549
"highlight2" >NRF2↓, "highlight2" >GSH↓, "highlight2" >ChemoSen↑, "highlight2" >HO-1↓,
2588- LT,  Chemo,    Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway
- in-vitro, CRC, HCT116
"highlight2" >NRF2↓, "highlight2" >NQO1↓, "highlight2" >HO-1↓, "highlight2" >GSH↓, "highlight2" >ChemoSen↑,
2589- LT,  Chemo,    Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway
- in-vitro, BC, MDA-MB-231
"highlight2" >NRF2↓, "highlight2" >HO-1↓, "highlight2" >ChemoSen↑, "highlight2" >CSCs↓, "highlight2" >SIRT1↓,
2595- LT,    Regulation of Nrf2/ARE Pathway by Dietary Flavonoids: A Friend or Foe for Cancer Management?
- Review, Var, NA
"highlight2" >*NRF2↑, "highlight2" >NRF2↓, "highlight2" >NRF2⇅,
2903- LT,    Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in gliomablastoma
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG - in-vivo, NA, NA
"highlight2" >ER Stress↑, "highlight2" >ROS↑, "highlight2" >PERK↑, "highlight2" >eIF2α↑, "highlight2" >ATF4↑, "highlight2" >CHOP↑, "highlight2" >Casp12↑, "highlight2" >eff↓, "highlight2" >UPR↑, "highlight2" >MMP↓, "highlight2" >Cyt‑c↑, "highlight2" >Bcl-2↓, "highlight2" >BAX↑, "highlight2" >TumCG↓, "highlight2" >Weight∅, "highlight2" >ALAT∅, "highlight2" >AST∅,
2904- LT,    Luteolin from Purple Perilla mitigates ROS insult particularly in primary neurons
- in-vitro, Park, SK-N-SH - in-vitro, AD, NA
"highlight2" >*ROS↓, "highlight2" >*neuroP↑, "highlight2" >*MMP↑, "highlight2" >*Catalase↑, "highlight2" >*GSH↑, "highlight2" >selectivity↑, "highlight2" >*eff↑, "highlight2" >*Cyt‑c↓,
2905- LT,    Luteolin blocks the ROS/PI3K/AKT pathway to inhibit mesothelial-mesenchymal transition and reduce abdominal adhesions
- in-vivo, NA, HMrSV5
"highlight2" >*ROS↓, "highlight2" >*p‑Akt↓, "highlight2" >*Vim↓, "highlight2" >*E-cadherin↑, "highlight2" >*PI3K↓,
2906- LT,    Luteolin, a flavonoid with potentials for cancer prevention and therapy
- Review, Var, NA
"highlight2" >*Inflam↓, "highlight2" >AntiCan↑, "highlight2" >antiOx⇅, "highlight2" >Apoptosis↑, "highlight2" >TumCP↓, "highlight2" >TumMeta↓, "highlight2" >angioG↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >NF-kB↓, "highlight2" >XIAP↓, "highlight2" >P53↑, "highlight2" >*ROS↓, "highlight2" >*GSTA1↑, "highlight2" >*GSR↑, "highlight2" >*SOD↑, "highlight2" >*Catalase↑, "highlight2" >*other↓, "highlight2" >ROS↑, "highlight2" >Dose↝, "highlight2" >chemoP↑, "highlight2" >NF-kB↓, "highlight2" >JNK↑, "highlight2" >p27↑, "highlight2" >P21↑, "highlight2" >DR5↑, "highlight2" >Casp↑, "highlight2" >Fas↑, "highlight2" >BAX↑, "highlight2" >MAPK↓, "highlight2" >CDK2↓, "highlight2" >IGF-1↓, "highlight2" >PDGF↓, "highlight2" >EGFR↓, "highlight2" >PKCδ↓, "highlight2" >TOP1↓, "highlight2" >TOP2↓, "highlight2" >Bcl-xL↓, "highlight2" >FASN↓, "highlight2" >VEGF↓, "highlight2" >VEGFR2↓, "highlight2" >MMP9↓, "highlight2" >Hif1a↓, "highlight2" >FAK↓, "highlight2" >MMP1↓, "highlight2" >Twist↓, "highlight2" >ERK↓, "highlight2" >P450↓, "highlight2" >CYP1A1↓, "highlight2" >CYP1A2↓, "highlight2" >TumCCA↑,
2907- LT,    Protective effect of luteolin against oxidative stress‑mediated cell injury via enhancing antioxidant systems
- in-vitro, Nor, NA
"highlight2" >*ROS↓, "highlight2" >*Casp9↓, "highlight2" >*Casp3↓, "highlight2" >*Bcl-2↑, "highlight2" >*BAX↓, "highlight2" >*GSH↑, "highlight2" >*SOD↑, "highlight2" >*Catalase↑, "highlight2" >*GPx↑, "highlight2" >*HO-1↑, "highlight2" >*antiOx↑, "highlight2" >*lipid-P↓, "highlight2" >*p‑γH2AX↓, "highlight2" >eff↑,
2908- LT,    Luteolin attenuates neutrophilic oxidative stress and inflammatory arthritis by inhibiting Raf1 activity
- in-vitro, Arthritis, NA
"highlight2" >*ROS↓, "highlight2" >*p‑ERK↓, "highlight2" >*p‑MEK↓, "highlight2" >*Raf↓,
973- LT,    Luteolin impairs hypoxia adaptation and progression in human breast and colon cancer cells
- in-vitro, CRC, HCT116 - in-vitro, BC, MDA-MB-231
"highlight2" >Apoptosis↑, "highlight2" >necrosis↑, "highlight2" >TumAuto↑, "highlight2" >HIF-1↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 58

Results for Effect on Cancer/Diseased Cells:
AEG1↓,1,   AIF↑,1,   Akt↓,3,   Akt↑,1,   p‑Akt↓,2,   AKT1↓,2,   Akt2↓,1,   ALAT∅,1,   ALDH1A1↓,1,   angioG↓,4,   AntiCan↑,1,   antiOx⇅,1,   APAF1↑,1,   Apoptosis↓,1,   Apoptosis↑,12,   AR↓,2,   ASC↓,1,   AST∅,1,   ATF2↓,1,   ATF4↑,2,   p‑ATF4↝,1,   cl‑ATF6↑,1,   ATP↓,1,   AXL↓,1,   BAD↑,1,   BAX↑,8,   Bax:Bcl2↑,1,   Bcl-2↓,8,   Bcl-xL↓,2,   Beclin-1↑,3,   BID↑,1,   BioAv↓,1,   BioAv↑,3,   BNIP3↑,1,   BOK↑,1,   Ca+2↑,2,   cachexia↓,1,   cardioP↑,1,   Casp↑,1,   Casp1↓,1,   Casp12↑,2,   cl‑Casp12↑,1,   cl‑Casp12↝,1,   Casp3↑,7,   cl‑Casp3↑,1,   Casp7↑,1,   Casp8↑,3,   cl‑Casp8↑,1,   Casp9↑,5,   cl‑Casp9↑,1,   proCasp9↓,1,   Catalase↓,3,   Catalase↑,1,   CD34↓,1,   CDC2↓,2,   Cdc42↓,1,   CDK2↓,5,   CDK4↓,2,   CDK6↓,1,   CEA↓,1,   cFos↑,1,   chemoP↑,4,   ChemoSen↓,1,   ChemoSen↑,7,   CHOP↑,3,   p‑CHOP↝,1,   CLDN1↓,1,   cMET↓,1,   cMyc↓,3,   p‑cMyc↑,1,   COX2↓,1,   CSCs↓,1,   CXCR4↓,1,   cycA1↑,1,   CycB↓,2,   cycD1↓,3,   cycE↓,1,   CYP19↓,1,   CYP1A1↓,2,   CYP1A2↓,1,   Cyt‑c↑,5,   DNAdam↑,1,   DNMT1↓,1,   DNMT3A↓,1,   DNMTs↓,2,   Dose?,1,   Dose↝,1,   DR5↑,5,   E-cadherin↓,1,   E-cadherin↑,5,   ECM/TCF↓,1,   eff↓,4,   eff↑,4,   EGFR↓,1,   EGFR↑,1,   p‑EGFR↓,1,   eIF2α↑,2,   p‑eIF2α↑,2,   p‑eIF2α↝,1,   EM↑,1,   EMT↓,5,   ER Stress↑,5,   ERK↓,2,   ERK↑,1,   p‑ERK↓,2,   EZH2↓,2,   FADD↑,1,   FAK↓,3,   Fas↑,4,   FasL↑,1,   FASN↓,2,   Ferroptosis↑,1,   GDF15↓,1,   Glycolysis↓,2,   GPx↓,1,   GPx4↓,1,   GRP78/BiP↑,1,   GRP94↑,1,   GSH↓,5,   GSK‐3β↓,1,   p‑GSK‐3β↓,1,   GSR↓,1,   GSS↑,1,   GSTs↓,2,   GutMicro↑,1,   e-H2O2↓,1,   i-H2O2∅,1,   H3↓,1,   ac‑H3↓,1,   H4↓,1,   ac‑H4↓,1,   Half-Life↝,1,   HATs↓,1,   HDAC↓,4,   HER2/EBBR2↓,1,   HGF/c-Met↓,2,   HIF-1↓,1,   Hif1a↓,2,   HK2↓,1,   HO-1↓,6,   HO-1↑,1,   HSP90↓,2,   hTERT↓,3,   ICAM-1↓,1,   IFN-γ↓,1,   IGF-1↓,1,   IKKα↓,1,   IL1↓,1,   IL18↓,1,   IL2↓,1,   IL2↑,1,   IL6↓,2,   IL8↓,1,   iNOS↓,1,   Iron↑,1,   IronCh↑,1,   ITGB1↓,1,   JNK↓,1,   JNK↑,2,   p‑JNK↑,1,   LC3B-II↑,1,   LC3II↑,2,   MAPK↓,3,   MAPK↑,1,   Mcl-1↓,2,   MDA↑,1,   MDM2↓,2,   p‑MDM2↓,1,   MDR1↓,2,   p‑MEK↓,1,   MET↓,1,   p‑MET↓,1,   MMP↓,5,   MMP1↓,1,   MMP2↓,4,   MMP9↓,4,   MSCmark↓,1,   mtDam↑,2,   mTOR↓,1,   Myc↓,1,   N-cadherin↓,5,   NAIP↓,1,   necrosis↑,1,   NF-kB↓,8,   p‑NF-kB↑,1,   NICD↓,1,   NLRP3↓,1,   NOTCH↓,1,   NOTCH1↓,2,   NQO1↓,2,   NRF2↓,8,   NRF2↑,2,   NRF2⇅,1,   NSE↓,1,   P21↑,3,   p27↑,1,   p38↑,1,   p‑p38↑,2,   P450↓,1,   P53↑,4,   p‑p65↓,1,   PARP↑,1,   cl‑PARP↑,1,   PCNA↓,1,   PD-1↓,1,   PD-L1↓,1,   PDGF↓,1,   PERK↑,2,   p‑PERK↝,1,   PI3K↓,4,   p‑PI3K↓,1,   PKCδ↓,1,   PKM2↓,1,   PTEN↓,1,   Rac1↓,1,   RadioS↑,3,   RAS↓,1,   Rho↓,1,   ROS↓,2,   ROS↑,11,   selectivity↑,2,   SIRT1↓,2,   Snail↓,3,   SOD↓,6,   SOD2↓,1,   SOX4↓,1,   p‑Src↓,1,   SREBP2↓,1,   STAT3↓,3,   p‑STAT3↓,4,   p‑STAT6↓,1,   survivin↓,2,   TAZ↓,2,   Telomerase↓,2,   TET1↑,2,   TET2↓,1,   TET3↑,1,   TGF-β↓,1,   TIMP1↑,1,   TIMP2↑,1,   TNF-α↓,2,   TOP1↓,1,   TOP2↓,1,   Trx1↑,1,   TrxR1↓,1,   TumAuto↑,3,   TumCCA↑,8,   TumCD↑,1,   TumCG↓,4,   TumCMig↓,3,   TumCP↓,9,   tumCV↓,2,   TumMeta↓,2,   Twist↓,2,   Tyro3↓,1,   UPR↑,1,   VEGF↓,4,   VEGFR2↓,2,   Vim↓,3,   Vim↑,1,   VitC↓,1,   VitE↓,1,   Weight∅,1,   Wnt↓,2,   XIAP↓,4,   YAP/TEAD↓,2,   ZO-1↑,1,   β-catenin/ZEB1↓,2,  
Total Targets: 268

Results for Effect on Normal Cells:
AChE↓,3,   ACSL4∅,1,   p‑Akt↓,1,   ALAT↓,1,   AMPK↑,2,   AntiAg↑,2,   antiOx↑,8,   AP-1↓,1,   AST↓,1,   ATF4↓,1,   ATP↑,1,   Aβ↓,3,   BACE↓,1,   BAX↓,1,   Bax:Bcl2↓,1,   BBB↑,3,   Bcl-2↑,1,   BDNF↑,2,   Beclin-1↓,1,   BioAv↓,3,   BioAv↑,1,   BioAv↝,1,   BloodF↑,1,   cardioP↑,1,   Casp1↓,1,   Casp3↓,3,   Casp9↓,1,   Casp9↑,1,   Catalase↑,5,   CHOP↓,1,   cognitive↑,2,   COX2↓,2,   COX2∅,1,   CREB↑,1,   Cyt‑c↓,1,   E-cadherin↑,1,   eff↑,4,   ER Stress↓,1,   p‑ERK↓,1,   Ferroptosis↓,1,   GPx↑,2,   GPx4∅,1,   GRP78/BiP↑,1,   GSH↑,5,   GSK‐3β↓,2,   GSR↑,2,   GSTA1↑,1,   GSTs↑,2,   GutMicro↑,1,   Half-Life↝,1,   HDAC2↓,1,   hepatoP↑,1,   HO-1↑,3,   HO-1∅,1,   IFN-γ↓,1,   IL10↑,1,   IL18↓,1,   IL1β↓,3,   IL2↓,1,   IL33↓,1,   IL6↓,3,   IL8↓,1,   Inflam↓,5,   iNOS↓,1,   IronCh↑,1,   p‑JNK↓,1,   LDHA↑,1,   lipid-P↓,5,   MDA↓,2,   p‑MEK↓,1,   memory↑,1,   p‑MKK4↑,1,   MMP↑,2,   MMP1↓,1,   p‑mTOR↓,1,   neuroP↑,5,   NF-kB↓,2,   p‑NF-kB↓,1,   NLRP3↓,1,   NO↓,1,   NQO1↑,1,   NRF2↓,1,   NRF2↑,4,   NRF2∅,1,   other↓,2,   p‑p38↓,1,   PDGF↓,1,   PGE2↓,1,   PI3K↓,1,   PPARα↑,1,   PPARγ↑,1,   PrxII↑,1,   Raf↓,1,   RenoP↑,1,   ROS↓,15,   SIRT1↑,2,   SOD↑,7,   SREBP1↓,1,   tau↓,2,   p‑tau↓,2,   TLR4↓,1,   TNF-α↓,2,   toxicity↓,1,   toxicity↑,1,   TrkB↑,1,   TXNIP↓,1,   UPR↑,1,   Vim↓,1,   ZO-1↑,1,   p‑γH2AX↓,1,  
Total Targets: 110

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:118  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page